HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (52) Citing Articles via Google Scholar Google Scholar Articles by Costa, R. A. Articles by Scott, I. U. Search for Related Content PubMed PubMed Citation Articles by Costa, R. A. Articles by Scott, I. U.

Intravitreal Bevacizumab for Choroidal Neovascularization Caused by AMD (IBeNA Study): Results of a Phase 1 Dose-Escalation Study

¹From the U.D.A.T. Macular Imaging and Treatment Division, Hospital de Olhos de Araraquara, Araraquara, SP, Brazil; the ²Retina and Vitreous Section, Department of Ophthalmology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil; and the ³Departments of Ophthalmology and Health Evaluation Sciences, Penn State College of Medicine, Hershey, Pennsylvania.

PURPOSE. To evaluate the safety of three dose regimens of intravitreal bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) for the management of choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).

METHODS. This was a prospective, nonrandomized open-label study of 45 patients with AMD and subfoveal CNV. A standardized ophthalmic evaluation was performed at baseline and at weeks 1, 6, and 12 (±1) after a single intravitreous injection (1.0, 1.5, or 2.0 mg) of bevacizumab. Main outcomes measures include clinical evidence of toxicity and complications. Changes in best corrected visual acuity (BCVA) and lesion characteristics–macular morphology were also evaluated.

RESULTS. The most common adverse events were conjunctival hyperemia and subconjunctival hemorrhage at the injection site. Mean BCVA improved from baseline throughout the study (P < 0.001; ANOVA with Geisser-Greenhouse correction). Compared with baseline, BCVA was improved at week 1 (P = 0.001), week 6 (P < 0.001), and week 12 (P = 0.001; Dunnett test). At week 12, the lesion area and CNV area were stable or decreased in 79.1% (34/43) and in 74.4% (32/43) of patients, respectively, with no deterioration of macular architecture observed in 83.7% (36/43). A dose-related change in BCVA (in Early Treatment Diabetic Retinopathy Study [ETDRS] lines) was observed at week 12 (1.0 mg [+0.3 line]; 1.5 mg [+0.6 line]; and 2.0 mg [+1.0 line]; P = 0.02; nonparametric test for ordered groups).

CONCLUSIONS. A single intravitreal bevacizumab injection was well tolerated and, except for minor transient local adverse events, no other adverse events were observed. In the short-term, treatment was associated with vision stabilization or improvement and no unfavorable neovascular lesion–macular changes in most patients.

This article has been cited by other articles:

				D da R Lucena, J A S Ribeiro, R A Costa, J C Barbosa, I U Scott, L L de Figueiredo-Pontes, and R Jorge Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study) Br. J. Ophthalmol., May 1, 2009; 93(5): 688 - 691. [Abstract] [Full Text] [PDF]

				S. Kaempf, S. Johnen, A. K. Salz, A. Weinberger, P. Walter, and G. Thumann Effects of Bevacizumab (Avastin) on Retinal Cells in Organotypic Culture Invest. Ophthalmol. Vis. Sci., July 1, 2008; 49(7): 3164 - 3171. [Abstract] [Full Text] [PDF]

				G Weigert, S Michels, S Sacu, A Varga, F Prager, W Geitzenauer, and U Schmidt-Erfurth Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study Br. J. Ophthalmol., March 1, 2008; 92(3): 356 - 360. [Abstract] [Full Text] [PDF]

				E. Budzynski, J. H. Smith, P. Bryar, G. Birol, and R. A. Linsenmeier Effects of Photocoagulation on Intraretinal PO2 in Cat Invest. Ophthalmol. Vis. Sci., January 1, 2008; 49(1): 380 - 389. [Abstract] [Full Text] [PDF]

				L Paccola, R A Costa, M S Folgosa, J C Barbosa, I U Scott, and R Jorge Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study) Br. J. Ophthalmol., January 1, 2008; 92(1): 76 - 80. [Abstract] [Full Text] [PDF]

				A. Lux, H. Llacer, F. M A Heussen, and A. M Joussen Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions Br. J. Ophthalmol., October 1, 2007; 91(10): 1318 - 1322. [Abstract] [Full Text] [PDF]

				S. S Lynch and C. M Cheng Bevacizumab for Neovascular Ocular Diseases Ann. Pharmacother., April 1, 2007; 41(4): 614 - 625. [Abstract] [Full Text] [PDF]